Kelowna, BC / August 24, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) is very pleased to announce potential industry-changing achievements in enhanced gastro-intestinal absorption of cannabidiol (CBD) utilizing Lexaria’s patent pending technology. The recent thirdparty testing was conducted in two phases of in vitro tests beginning in June and completed in August, 2015.

The independent laboratory results have delivered average CBD permeability of 499% of baseline permeability, compared to CBD permeability without Lexaria’s technology. These results exceed Company expectations.

This was assessed in a strictly controlled, in vitro experiment using a human intestinal tissue model. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patent-pending formulation and process enhancements. Lexaria believes that its in vitro findings provide compelling evidence of the intestinal absorption enhancing capabilities of its technology, based on which it is exploring opportunities to progress to more advanced, follow-on bioavailability testing in animals.

Boulder, Colorado-based Tradiv is raising a $1 million round as it gears up to launch its B2B marketplace for cannabis cultivators, marijuana infused product companies, and dispensaries.

That’s right: The B2B pot ecosystem is unfolding right before our eyes.

Backed by Cannabis accelerator CanopyBoulder and accelerator partner Micah Tapman, Tradiv revealed the raise in a public filing with the U.S. Securities and Exchange Commission. The weed startup has so far raised $650,000, according to the filing — at least $20,000 of which likely came from CanopyBoulder, in exchange for a whopping 9.5 percent equity stake. The filing also lists Emily Paxhia, partner of Cannabis-only fund Poseidon Asset Management; and former Microsoft Surface manager, Nick Hofmeister.

Pennsylvania drugmaker Zynerba Pharmaceuticals ($ZYNE) is making its way to Wall Street with some cannabis-derived treatments for central nervous system disorders, raising $42 million in an IPO.

The company priced 3 million shares at $14 each, the middle of its range, and set aside another 450,000 shares for its underwriters to line up for as much as $51.8 million in total.

With the proceeds, Zynerba will press forward with a pair of early-stage transdermal patches that mete out cannabinoid chemicals to treat a host of CNS ailments. ZYN002, slated to enter clinical trials in the second half, has shown promise in refractory epilepsy, Fragile X syndrome and osteoarthritis pain, the company said. And ZYN001, in line for Phase I next year, targets fibromyalgia and peripheral neuropathic pain.

The promise of cannabis-derived pharmaceuticals has drawn a slew of companies to the field over the past few years, including GW Pharmaceuticals ($GWPH) and Insys Therapeutics ($INSY). But unlike its further-along competitors, Zynerba's treatments are synthetically manufactured and don't require growing and maintaining cannabis plants, which the company bills as a practical and financial advantage. Furthermore, Zynerba's transdermal therapies get their active ingredients straight into the circulatory system, avoiding the bioavailability issues that can plague oral treatments that must first navigate the stomach and liver.

Zynerba is led by CEO Armando Anido, appointed in 2014 after stints at the helm of Auxilium Pharmaceuticals, acquired by Endo Pharmaceutical ($ENDP) for about $2.6 billion, and NuPathe, which went to Teva ($TEVA) for $144 million last year.

Meanwhile, biotech's ongoing IPO boom has continued unabated into the second half of 2015, marked by a record debut for Patrick Soon-Shiong's NantKwest ($NK). And the queue of drug developers angling to go public remains full, as Zynerba joins a group including gene therapy outfit Gensight Biologics and food allergy biotech Aimmune Therapeutics.

Economy of Scale - The cost advantage that arises with increased output of a product. Economies of scale arise because of the inverse relationship between the quantity produced and per-unit fixed costs; i.e. the greater the quantity of a good produced, the lower the per-unit fixed cost because these costs are shared over a larger number of goods. Economies of scale may also reduce variable costs per unit because of operational efficiencies and synergies. Economies of scale can be classified into two main types: Internal – arising from within the company; and External – arising from extraneous factors such as industry size. – “Investopedia”

I am constantly asked “how can I expand my cannabis business across state borders?” I am then forced to explain how the U.S. system of federalism works. Even though medical and/or recreational use of cannabis may be legal in your state, it is not legal on a federal level. Why? This boils down to the same issue concerning banking for the cannabis industry – the Schedule I Classification of cannabis makes its possession, use, cultivation and/or sale a federally illegal activity. Then logically following, from a federal perspective, the proceeds of activities involving Schedule I “drugs” are the proceeds of illegal activities.

Constitutional law then forces us to examine two important issues – (i) Preemption and (ii) Interstate Commerce. The “Supremacy Clause” states that state laws which conflict or contradict federal law, are null and void. Federal law is therefore the “law of the land”. So in essence, all state legalization of cannabis, in any category, will not be “legally” recognized by the federal government with respect to law enforcement. These real battles are being fought every day in states that have legalized cannabis use. For the moment, the federal government seems to content to allow the great cannabis experimentation to continue, while occasionally issuing “safe-harbor” guidance that is quickly disregarded.

These days it’s harder than ever to break through, especially in an industry whose bandwagon is quickly filling up like the SF cable car. There is so much noise, everyone is screaming and trying to get their message across, staking their claim in the green rush. It’s great in the sense that without gatekeepers more people are able to express their ideas, but the downside is that it’s harder than ever to actually be heard. I, personally, like when the best ideas win.

So, how do you find your breakthrough idea? Many people know generally where they want to go, but it takes more than that. There are five major ways to get to your “idea destination”. You don’t even have to do all five. Pick one and execute it well. That’s enough to make your name in the cannabis industry.

Start with a niche strategy then expand strategically outward

You can’t just say I’m going to be the expert in something. In that category, you will compete with the entire world. You have to narrow it down. The secret to that however, is that you don’t want to be pigeonholed doing that. You need to move into new territory from there. It’s all about circling the area around a niche. A good niche is one that you can become the master of, because the big players in the industry only talk about it periodically. Where do you get the seed for finding a niche? Well, solving your own problem is one way. If you are in a situation, others are too. Also, draw from your personal experiences. Notice needs and find a solution.